These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21447293)

  • 1. [Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease].
    Joly D
    Med Sci (Paris); 2011 Mar; 27(3):249-51. PubMed ID: 21447293
    [No Abstract]   [Full Text] [Related]  

  • 2. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
    Ponticelli C; Locatelli F
    Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutation detection of PKD1 gene in patients with autosomal dominant polycystic kidney diseases].
    Li L; Li LY; Zhong CG; Gao BD; Lu GX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):666-9. PubMed ID: 18067079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
    [No Abstract]   [Full Text] [Related]  

  • 6. [Gene diagnosis of autosomal dominant polycystic kidney disease type 2 using microsatellite DNA tightly linked to polycystic kidney disease gene 2].
    Zhang WL; Zhang DY; Wu YM; Sun TM; Mei CL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Aug; 21(4):325-8. PubMed ID: 15300626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR inhibitors in polycystic kidney disease.
    Watnick T; Germino GG
    N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
    [No Abstract]   [Full Text] [Related]  

  • 8. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adult dominant polycystic kidney disease: molecular mechanisms and new therapeutic possibilities].
    Rodríguez Pérez JC; Torres MJ
    Nefrologia; 2006; 26(6):651-2. PubMed ID: 17227240
    [No Abstract]   [Full Text] [Related]  

  • 10. [Recent advances in studies on autosomal dominant adult polycystic kidney disease].
    Yu CW; Zhang SZ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):402-5. PubMed ID: 20677145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic analysis (PKD2) of autosomal dominant polycystic kidney disease].
    Gómez PF; Moro EC; García-Cosmes P; Sarmiento RG; Romo JM
    Nefrologia; 2009; 29(6):562-8. PubMed ID: 19936001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
    Rapoport J
    QJM; 2007 Jan; 100(1):1-9. PubMed ID: 17164322
    [No Abstract]   [Full Text] [Related]  

  • 13. mTOR signaling in polycystic kidney disease.
    Ibraghimov-Beskrovnaya O; Natoli TA
    Trends Mol Med; 2011 Nov; 17(11):625-33. PubMed ID: 21775207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutation as mechanism for cyst formation in autosomal dominant polycystic kidney disease.
    Qian F; Watnick TJ
    Mol Genet Metab; 1999 Oct; 68(2):237-42. PubMed ID: 10527675
    [No Abstract]   [Full Text] [Related]  

  • 15. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of ciliary trafficking of polycystin-2 and the pathogenesis of autosomal dominant polycystic kidney disease.
    Cai Y; Tang Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Feb; 35(2):93-9. PubMed ID: 20197605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
    Canaud G; Knebelmann B; Harris PC; Vrtovsnik F; Correas JM; Pallet N; Heyer CM; Letavernier E; Bienaimé F; Thervet E; Martinez F; Terzi F; Legendre C
    Am J Transplant; 2010 Jul; 10(7):1701-6. PubMed ID: 20642692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New strategy for the treatment of autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2015; 57(1):254-61. PubMed ID: 25735085
    [No Abstract]   [Full Text] [Related]  

  • 19. Human gene mutations. Gene symbol: PKD1. Disease: Polycystic kidney disease.
    Daniells C; Maheshwar M; Lazarou L; Davies F; Coles G; Ravine D
    Hum Genet; 1998 Jan; 102(1):127. PubMed ID: 9490292
    [No Abstract]   [Full Text] [Related]  

  • 20. New options in the treatment of autosomal dominant polycystic kidney disease.
    Kazancioglu R; Gursu M
    Ren Fail; 2015 May; 37(4):535-41. PubMed ID: 25682970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.